Hyunsoon Cho1, Angela B Mariotto2, Lisa M Schwartz2, Jun Luo2, Steven Woloshin2. 1. Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD (HC, ABM); Division of Cancer Registration and Surveillance, National Cancer Center, Goyang-si Gyeonggi-do, Korea (HC); Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH, Geisel School of Medicine at Dartmouth, Hanover NH, Veterans Affairs Outcomes Group, Department of Veterans Affairs Medical Center, White River Junction, VT (LMS, SW); Information Management Services, Inc., Calverton, MD (JL). hscho@ncc.re.kr hyunsoon.cho@gmail.com. 2. Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD (HC, ABM); Division of Cancer Registration and Surveillance, National Cancer Center, Goyang-si Gyeonggi-do, Korea (HC); Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH, Geisel School of Medicine at Dartmouth, Hanover NH, Veterans Affairs Outcomes Group, Department of Veterans Affairs Medical Center, White River Junction, VT (LMS, SW); Information Management Services, Inc., Calverton, MD (JL).
Abstract
BACKGROUND: It is often assumed that increases in cancer survival reflect true progress against cancer. This is true when these increases are accompanied by decreased burden of disease: Fewer people being diagnosed or dying from cancer (ie, decreased incidence and mortality). But increased survival can also occur even when incidence is increasing and mortality is unchanged. OBJECTIVE: To use trends in cancer burden-incidence and mortality-to illustrate when changes in survival reflect true progress. METHODS: Using data from 1975 to 2010 collected by the Surveillance, Epidemiology, and End Results Program (incidence, survival) and the National Center for Health Statistics (mortality), we analyzed US trends in five-year relative survival, age-adjusted incidence, and mortality for selected cancers to identify patterns that do and do not reflect progress. RESULTS: Among the nine common cancers examined, survival increased in seven, and changed little or not at all for two. In some cases, increased survival was accompanied by decreased burden of disease, reflecting true progress. For example, from 1975 to 2010, five-year survival for colon cancer patients improved (from 48% to 68%) while cancer burden fell: Fewer cases (incidence decreased from 60 to 41 per 100,000) and fewer deaths (mortality decreased from 28 to 16 per 100,000), a pattern explained by both increased early detection (with removal of cancer precursors) and more effective treatment. In other cases, however, increased survival did not reflect true progress. In melanoma, kidney, and thyroid cancer, five-year survival increased but incidence increased with no change in mortality. This pattern suggests overdiagnosis from increased early detection, an increase in cancer burden. CONCLUSIONS: Changes in survival must be interpreted in the context of incidence and mortality. Increased survival only represents progress when accompanied by a reduction in incidence, mortality, or ideally both. Published by Oxford University Press 2014.
BACKGROUND: It is often assumed that increases in cancer survival reflect true progress against cancer. This is true when these increases are accompanied by decreased burden of disease: Fewer people being diagnosed or dying from cancer (ie, decreased incidence and mortality). But increased survival can also occur even when incidence is increasing and mortality is unchanged. OBJECTIVE: To use trends in cancer burden-incidence and mortality-to illustrate when changes in survival reflect true progress. METHODS: Using data from 1975 to 2010 collected by the Surveillance, Epidemiology, and End Results Program (incidence, survival) and the National Center for Health Statistics (mortality), we analyzed US trends in five-year relative survival, age-adjusted incidence, and mortality for selected cancers to identify patterns that do and do not reflect progress. RESULTS: Among the nine common cancers examined, survival increased in seven, and changed little or not at all for two. In some cases, increased survival was accompanied by decreased burden of disease, reflecting true progress. For example, from 1975 to 2010, five-year survival for colon cancerpatients improved (from 48% to 68%) while cancer burden fell: Fewer cases (incidence decreased from 60 to 41 per 100,000) and fewer deaths (mortality decreased from 28 to 16 per 100,000), a pattern explained by both increased early detection (with removal of cancer precursors) and more effective treatment. In other cases, however, increased survival did not reflect true progress. In melanoma, kidney, and thyroid cancer, five-year survival increased but incidence increased with no change in mortality. This pattern suggests overdiagnosis from increased early detection, an increase in cancer burden. CONCLUSIONS: Changes in survival must be interpreted in the context of incidence and mortality. Increased survival only represents progress when accompanied by a reduction in incidence, mortality, or ideally both. Published by Oxford University Press 2014.
Authors: Angela B Mariotto; Anne-Michelle Noone; Nadia Howlader; Hyunsoon Cho; Gretchen E Keel; Jessica Garshell; Steven Woloshin; Lisa M Schwartz Journal: J Natl Cancer Inst Monogr Date: 2014-11
Authors: Yu Shen; Ying Yang; Lurdes Y T Inoue; Mark F Munsell; Anthony B Miller; Donald A Berry Journal: J Natl Cancer Inst Date: 2005-08-17 Impact factor: 13.506
Authors: Michel P Coleman; Manuela Quaresma; Franco Berrino; Jean-Michel Lutz; Roberta De Angelis; Riccardo Capocaccia; Paolo Baili; Bernard Rachet; Gemma Gatta; Timo Hakulinen; Andrea Micheli; Milena Sant; Hannah K Weir; J Mark Elwood; Hideaki Tsukuma; Sergio Koifman; Gulnar Azevedo E Silva; Silvia Francisci; Mariano Santaquilani; Arduino Verdecchia; Hans H Storm; John L Young Journal: Lancet Oncol Date: 2008-07-17 Impact factor: 41.316
Authors: Vicki B Benard; Meg Watson; Mona Saraiya; Rhea Harewood; Julie S Townsend; Antoinette M Stroup; Hannah K Weir; Claudia Allemani Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Thomas B Richards; S Jane Henley; Mary C Puckett; Hannah K Weir; Bin Huang; Thomas C Tucker; Claudia Allemani Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Janis Campbell; Krupa Gandhi; Anne Pate; Amanda Janitz; Amber Anderson; Robin Kinnard; Kai Ding Journal: J Okla State Med Assoc Date: 2016 Jul-Aug
Authors: Mimi R Borrelli; Abra H Shen; Gordon K Lee; Arash Momeni; Michael T Longaker; Derrick C Wan Journal: Ann Plast Surg Date: 2019-10 Impact factor: 1.539
Authors: Angela B Mariotto; Anne-Michelle Noone; Nadia Howlader; Hyunsoon Cho; Gretchen E Keel; Jessica Garshell; Steven Woloshin; Lisa M Schwartz Journal: J Natl Cancer Inst Monogr Date: 2014-11
Authors: Gonçalo Forjaz de Lacerda; Scott P Kelly; Joana Bastos; Clara Castro; Alexandra Mayer; Angela B Mariotto; William F Anderson Journal: Cancer Epidemiol Date: 2018-03-13 Impact factor: 2.984